Actively Recruiting

Phase 2
Age: 18Years - 50Years
FEMALE
NCT06577909

Prednisone Plus IVIg vs. Prednisone for ITP During Pregnancy

Led by Peking University People's Hospital · Updated on 2024-08-29

100

Participants Needed

1

Research Sites

114 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This is a prospective, randomized, open-label, multicenter clinical trial study to compare the efficacy and safety of prednisone plus IVIg to prednisone monotherapy in the treatment of immune thrombocytopenia (ITP) in pregnancy.

CONDITIONS

Official Title

Prednisone Plus IVIg vs. Prednisone for ITP During Pregnancy

Who Can Participate

Age: 18Years - 50Years
FEMALE

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 18-50 years old
  • Diagnosed with immune thrombocytopenia
  • Pregnant with ITP and no prior ITP-specific treatments during this pregnancy
  • Gestational age of at least 12 weeks
  • Platelet count less than 30 x 10^9/L, with or without bleeding symptoms
  • Able and willing to sign written informed consent
Not Eligible

You will not qualify if you...

  • Diagnosed with other autoimmune diseases or positive antibody tests (ANA >1:80, anti-cardiolipin antibodies, lupus anticoagulant, or positive Coombs' test)
  • Thrombocytopenia caused by pregnancy-specific conditions such as gestational thrombocytopenia, preeclampsia, HELLP syndrome, or acute fatty liver of pregnancy
  • Secondary thrombocytopenia due to drugs, vaccines, lymphoproliferative disorders, severe infection, liver cirrhosis, or similar causes
  • Other diseases that may cause thrombocytopenia including malignancies, megaloblastic anemia, aplastic anemia, myelodysplasia, myeloid fibrosis, DIC, thrombotic thrombocytopenic purpura, or hemolytic uremic syndrome
  • Current infection with HIV, hepatitis B, or hepatitis C viruses
  • Severe heart, kidney, liver, or respiratory dysfunction
  • History of mental illness
  • Allergic reaction to prednisone or IVIg

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Peking University Insititute of Hematology, Peking University People's Hospital

Beijing, Beijing Municipality, China, 100010

Actively Recruiting

Loading map...

Research Team

X

Xiaohui Zhang, Professor

CONTACT

H

Haixia Fu, MD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here